Birchview Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-14,000
| Closed | -$563K | – | 74 |
|
|
2026
Q1 | $563K | Hold |
14,000
| – | – | 0.32% | 51 |
|
|
2025
Q4 | $352K | Hold |
14,000
| – | – | 0.21% | 57 |
|
|
2025
Q3 | $317K | Hold |
14,000
| – | – | 0.24% | 57 |
|
|
2025
Q2 | $242K | Hold |
14,000
| – | – | 0.24% | 56 |
|
|
2025
Q1 | $306K | Hold |
14,000
| – | – | 0.27% | 44 |
|
|
2024
Q4 | $447K | Hold |
14,000
| – | – | 0.36% | 36 |
|
|
2024
Q3 | $404K | Hold |
14,000
| – | – | 0.35% | 32 |
|
|
2024
Q2 | $537K | Sell |
14,000
-4,000
| -22% | -$181K | 0.5% | 31 |
|
|
2024
Q1 | $1.06M | Hold |
18,000
| – | – | 0.86% | 25 |
|
|
2023
Q4 | $1.08M | Hold |
18,000
| – | – | 0.84% | 27 |
|
|
2023
Q3 | $685K | Buy |
18,000
+6,000
| +50% | +$264K | 0.58% | 30 |
|
|
2023
Q2 | $1.09M | Hold |
12,000
| – | – | 0.82% | 21 |
|
|
2023
Q1 | $792K | Hold |
12,000
| – | – | 0.62% | 24 |
|
|
2022
Q4 | $621K | Hold |
12,000
| – | – | 0.44% | 29 |
|
|
2022
Q3 | $820K | Hold |
12,000
| – | – | 0.58% | 31 |
|
|
2022
Q2 | $543K | Hold |
12,000
| – | – | 0.4% | 36 |
|
|
2022
Q1 | $610K | Hold |
12,000
| – | – | 0.44% | 37 |
|
|
2021
Q4 | $567K | Hold |
12,000
| – | – | 0.37% | 41 |
|
|
2021
Q3 | $396K | Buy |
12,000
+4,000
| +50% | +$225K | 0.27% | 47 |
|
|
2021
Q2 | $506K | Hold |
8,000
| – | – | 0.3% | 43 |
|
|
2021
Q1 | $343K | Hold |
8,000
| – | – | 0.2% | 46 |
|
|
2020
Q4 | $458K | Hold |
8,000
| – | – | 0.26% | 42 |
|
|
2020
Q3 | $241K | Hold |
8,000
| – | – | 0.16% | 46 |
|
|
2020
Q2 | $261K | Hold |
8,000
| – | – | 0.16% | 47 |
|
|
2020
Q1 | $214K | Hold |
8,000
| – | – | 0.19% | 41 |
|
|
2019
Q4 | $245K | Buy |
+8,000
| New | +$221K | 0.18% | 44 |
|
|
2019
Q3 | – | Sell |
-8,000
| Closed | -$203K | – | 51 |
|
|
2019
Q2 | $203K | Buy |
+8,000
| New | +$163K | 0.12% | 43 |
|
Other funds holding APLS
Birchview Capital's APLS Position: Q2 2026 in Review
Birchview Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 14,000 shares — an estimated $563K sold.
Birchview Capital first reported a position in APLS in Q2 2019 and held it in 27 quarters. The position peaked at $1.09M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Birchview Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Birchview Capital sold 14,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $563K.
- Birchview Capital first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 27 quarters.
- Birchview Capital's Apellis Pharmaceuticals position peaked at $1.09M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.